Activity of Omadacycline in Rat Methicillin-Resistant Staphylococcus aureus Osteomyelitis

Melissa J. Karau, Suzannah M. Schmidt-Malan, Scott A. Cunningham, Jayawant N. Mandrekar, Bobbi S. Pritt, Tiffany R. Keepers, Alisa W. Serio, Surya Chitra, Robin Patel

Research output: Contribution to journalArticlepeer-review


Omadacycline, vancomycin, and rifampin, as well as rifampin combination therapies, were evaluated in an experimental rat model of methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis. All treatment groups had less MRSA recovered than salinetreated animals. The emergence of rifampin resistance was observed in 3 of 16 animals with rifampin monotherapy and none with rifampin combination therapy. After treatment, the median tibial bacterial loads were 6.04, 0.1, 4.81, and 5.24 log10 CFU/g for saline-, rifampin-, vancomycin-, and omadacycline-treated animals, respectively. Omadacycline or vancomycin administered with rifampin yielded no detectable MRSA. Omadacycline administered with rifampin deserves evaluation in humans as a potential treatment for osteomyelitis.

Original languageEnglish (US)
Article numbere01703-21
JournalAntimicrobial Agents and Chemotherapy
Issue number1
StatePublished - Jan 2022


  • Methicillin-resistant Staphylococcus aureus
  • Omadacycline
  • Osteomyelitis
  • Rifampin
  • Vancomycin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'Activity of Omadacycline in Rat Methicillin-Resistant Staphylococcus aureus Osteomyelitis'. Together they form a unique fingerprint.

Cite this